Investment
Features
FeesSafety
Academy
More
Pluang+

Compare GraniteShares 2x Long COIN Daily ETF (CONL) vs Neurocrine Biosciences Inc (NBIX) Price & Performance

GraniteShares 2x Long COIN Daily ETFTrade
Neurocrine Biosciences IncTrade

Price performance (Past 24H)

Key statistics

GraniteShares 2x Long COIN Daily ETF vs Neurocrine Biosciences Inc — how do they compare? GraniteShares 2x Long COIN Daily ETF trades at $4.1, while Neurocrine Biosciences Inc trades at $161.94 (market cap $16.76B). The key difference: Neurocrine Biosciences Inc is trading nearer its 52-week high, GraniteShares 2x Long COIN Daily ETF nearer its low. Which is the better fit depends on your goals.

CONLNBIX
Sector
Leveraged / InverseHealth
52-Week High
$48.70$185.50
52-Week Low
$3.93$123.10
Market Cap
$16.76B
Enterprise Value
$16.78B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

GraniteShares 2x Long COIN Daily ETF

CONL (GraniteShares 2x Long COIN Daily ETF) trades at $4.38, up 11.45% in the past 24 hours but remains significantly below year-to-date levels with a 67% decline. Technical indicators show a bearish trend with moving averages signaling sell pressure, while oscillators remain neutral. The ETF tracks Coinbase stock with 2x daily leverage, exposing investors to amplified volatility from cryptocurrency market movements.

The outlook remains challenging due to the volatility decay inherent in daily-reset leveraged products. While recent cryptocurrency strength provides potential upside, the structural design of CONL creates significant long-term erosion risk. Investors should understand the product's mechanics before considering positions in this high-risk instrument.

Neurocrine Biosciences Inc

Neurocrine Biosciences (NBIX) trades at $163.41, up 2.25% today, with a bearish technical signal but strong fundamentals including a 39% revenue growth in Q2 2026 and a net income margin of 20.91%. Recent news highlights Phase 1 trial initiation for a GLP-1/GIP/glucagon receptor agonist and leadership appointments, supporting growth prospects.

The outlook is positive with an analyst consensus price target of $208.82, implying 28% upside, driven by robust earnings beats and pipeline advancements. Risks include clinical trial outcomes and competitive pressures in biopharma, but institutional buying and high analyst buy ratings (86.49%) reflect confidence in execution.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About GraniteShares 2x Long COIN Daily ETF

CONL is a leveraged ETF that seeks to provide two times (2x) the daily performance of Coinbase Global (COIN) stock. It is designed for investors seeking magnified short-term exposure to the price movements of Coinbase.

Read more on CONL

About Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.

Read more on NBIX